The September rise in SP wasn’t due to a company announcement, but due to the Covid sentiment and media publicity on RATs.
Since then, there has been new supply agreements with AccessBio (arguably, not in favour of Atomo in the long term), delays in self-test approvals and a growing general public disinterest in Covid as everyone gets vaccinated and infection rates decline.
The hype was built on Covid. If this is no longer as relevant, I’d argue that this is a change in fundamentals (as would the declining SP).
Add to My Watchlist
What is My Watchlist?
